Brief: Outlook Therapeutics Provides Regulatory Update On U.S. FDA Review Of Lytenava

Outlook Therapeutics

31/12/2025 22:36

Dec 31 (Reuters) - Outlook Therapeutics Inc OTLK.O:

OUTLOOK THERAPEUTICS PROVIDES REGULATORY UPDATE ON U.S. FOOD AND DRUG ADMINISTRATION REVIEW OF ONS-5010/LYTENAVA™ (BEVACIZUMAB-VIKG) FOR THE TREATMENT OF WET AMD

OUTLOOK THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR ONS-5010 BLA

OUTLOOK THERAPEUTICS INC:  CURRENTLY EXPLORING ALL AVAILABLE PATHWAYS FOR POTENTIAL APPROVAL IN U.S

OUTLOOK THERAPEUTICS INC - FDA RECOMMENDS CONFIRMATORY EVIDENCE FOR ONS-5010 APPROVAL

OUTLOOK THERAPEUTICS INC: FDA HAS NOT INDICATED WHAT TYPE OF CONFIRMATORY EVIDENCE WOULD BE ACCEPTABLE

Source text: ID:nGNX8602ql

Further company coverage: OTLK.O

 ((Reuters.Briefs@thomsonreuters.com;))